
Higher-Dose Ivermectin for Outpatients With COVID-19, Trends in Cardiovascular Risk Factor Prevalence and Control in US Adults, Review of Chronic Lymphocytic Leukemia, and more
JAMA Editors' Summary
00:00
Introduction
Kirsten Bibbins-Domingo: This is the JAMA Editor's Summary, a review of important research and review articles appearing in the latest JAMA issue. The first article is from Dr. Nagian colleagues investigating the effect of a higher dose of Ivermectin versus placebo on time to sustained recovery in outpatients with COVID-19. Doctors London and Seymour provide an accompanying editorial on the ethics of clinical research and managing persistent uncertainty.
Transcript
Play full episode